Oncology Biochemistry and molecular biology Technology and innovation

Rhabdomyosarcoma Revealed: The Mutations Behind the Tumors

Targeted RNA sequencing identifies oncogenic alterations in 11 of 12 pediatric fusion-negative rhabdomyosarcoma cases, according to a recent study.

10/15/2025 News 2 min read

article Full Article Summary Notecard

Share

Study focused on fusion-negative rhabdomyosarcoma in children.
Tumors analyzed from 12 patients aged 6 days to 15 years.
Utilized targeted RNA sequencing for molecular insight.
High sensitivity and specificity achieved in detecting mutations.
Most tumors found in trunk and head/neck regions.
92 percent of tumors had oncogenic alterations.
Key mutations included those in RAS pathway and DICER1.
Important for future therapeutic strategies.